Objective
Study design
Results
Conclusion
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Obstetrics & GynecologyReferences
- Report of the Canadian Hypertension Society Consensus Conference: 3, pharmacologic treatment of hypertensive disorders in pregnancy.CMAJ. 1997; 157: 1245-1254
- The detection, investigation and management of hypertension in pregnancy: executive summary.Aust N Z J Obstet Gynaecol. 2000; 40: 133-138
- Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.Am J Obstet Gynecol. 2000; 183: S1-S22
- The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade.Br J Obstet Gynaecol. 1994; 101: 262-263
- Neuromuscular blockade with magnesium-sulfate and nifedipine.Am J Obstet Gynecol. 1989; 161: 35-36
- Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks.BJOG. 1993; 100: 959-961
- Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia?.Am J Obstet Gynecol. 1988; 159: 308-309
- Fortnightly review: management of hypertension in pregnancy.BMJ. 1999; 318: 1332-1336
- Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.BMJ. 2003; 327: 955-960
- The calcium antagonist controversy: a posthumous commentary.Am J Cardiol. 1998; 82: 35R-39R
- Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study.J Obstet Gynaecol Can. 2003; 25: 372-382
- Why mothers die 1997-1999: the confidential enquiries into maternal deaths in the UK.RCOG Press, London2001
- Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.Lancet. 2002; 359: 1877-1890
- Report of the Canadian Hypertension Society Consensus Conference: 1, definitions, evaluation and classification of hypertensive disorders in pregnancy.CMAJ. 1997; 157: 715-725
- Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.Acta Obstetricia et Gynecologica Scand. 2002; 81: 25-30
- Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol.Intens Care Med. 2002; 28: 1281-1286
- Nifedipine in the treatment of severe preeclampsia.Obstet Gynecol. 1991; 77: 331-337
- Oral nifedipine therapy in the management of severe preeclampsia.Int J Gynaecol Obstet. 1995; 49: 265-269
- Randomized, controlled trial of hydralazine versus nifedipine in preeclamptic women with acute hypertension.Clin Exper Hypertens Pregn. 1992; B11: 25-44
- A Randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.Am J Obstet Gynecol. 1999; 181: 858-861
- Sublingual nifedipine compared with intravenous hydralazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice.J Obstet Gynaecol Res. 1996; 22: 21-24
- Nifedipine in acute hypertensive emergencies in pregnancy.S Afr Med J. 1989; 76: 248-250
- Pre-eclampsia severa: nifedipina versus cloropromazina en el manejo del estado hipertensivo agudo.Rev Med IMSS. 1989; 27: 359-363
- Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension.Aust N Z J Obstet. Gynaecol. 1992; 32: 335-338
- A comparative study of intravenous isradipine and dihydralazine in the treatment of severe hypertension of pregnancy in black patients.Hypertens Pregn. 1997; 16: 1-9
- Manejo de la preeclampsia severa/eclampsia. comparacion entre nifedipine e hidralazina como medicamentos antihipertensivos.Ginec Obst Mex. 1993; 61: 76-79
Article info
Publication history
Footnotes
Supported by the British Columbia Research Institute for Children's and Women's Health, the Michael Smith Foundation for Health Research (L.A.M), and Drs. Magee and von Dadelszen receive research support from the British Columbia Research Institute for Children's and Women's Health, and the BC Women's Hospital Foundation (L.A.M. and P.vD.).